Drug firm Zydus Cadila today said it has received approval from the US health regulator to market anti-histamine Cyproheptadine Hydrochloride tablets in the US market.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Cyproheptadine Hydrochloride tablets in the strength of 4 mg, Cadila Healthcare said in a BSE filing.
The drug will be produced at the group’s formulation manufacturing facility at the pharma SEZ in Ahmedabad, it added.
The group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs), Cadila Healthcare said.
The tablets are used to relieve allergy symptoms such as hives, watery eyes, sneezing and itching eyes or nose, it added.
Shares of Cadila Healthcare were trading 2.78 per cent down at Rs 445.10 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.